NVCR - NovoCure: Projecting Glioblastoma And Mesothelioma Revenues
Shares of NovoCure (NVCR) were trading at $18/share when I introduced them as "revolutionizing cancer treatment" and at $21/share when I called them a "high conviction" pick. Just a few months later, shares in NovoCure trade comfortably over $45/share and for good reason. NovoCure is seeing continued robust growth and adoption of TTFields in glioblastoma. Additionally, full mesothelioma data was presented and NovoCure should begin to market TTFields for the indication in 2019.
The following article will provide a short history of NovoCure's revolutionary treatment and project future revenues from glioblastoma and mesothelioma.